Pizotifen (Pizotyline)
- Atc Codes:N02CX01
- CAS Codes:15574-96-6
- PHARMGKB ID:15574-96-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Sandomigran; Belgium: Sandomigran; Czech Republic: Sandomigran; Denmark: Sandomigrin; France: Sanmigran; Ireland: Sanomigran; Italy: Sandomigran; Luxembourg: Mosegor, Sandomigran; Netherlands: Sandomigran; Poland: Polomigran; Slovakia: Sandomigran; Spain: Mosegor, Sandomigrán; Sweden: Sandomigrin; UK: Pizotifen, Sanomigran.
North America
Canada: Sandomigran.
Latin America
Argentina: Sandomigrán; Brazil: Sandomigran.
Drug combinations
Chemistry
Pizotifen: C~19~H~21~NS. Mw: 295.44. (1) Piperidine, 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methyl-; (2) 4-(9,10-Dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine. CAS-15574-96-6 (1970).
Pharmacologic Category
Antimigraine Agents, Miscellaneous; Serotonin and Histamine Antagonist. (ATC-Code: N02CX01).
Mechanism of action
Mechanism of action in migraine prophylaxis not fully elucidated.
Therapeutic use
Migraine prophylaxis.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to pizotifen or any component of the formulation. Concurrent use of MAOIs. Gastric outlet obstruction (pyloroduodenal obstruction, stenosing pyloric ulcer).
Warnings and precautions
Anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention) limited (use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, benign prostatic hypertrophy, xerostomia, or visual problems, and in patients intolerant to anticholinergic agents, including tricyclic antidepressants, phenothiazines, or cyproheptadine). May cause CNS depression. Use with caution in cardiovascular disease, diabetes mellitus, narrow-angle glaucoma (may be exacerbated by cholinergic blockade), and in hepatic or renal impairment. Not for use in acute treatment of migraine attacks. Use with caution in myasthenia gravis (may be exacerbated by cholinergic blockade), and in obese patients. Effects may be potentiated when used with other sedative drugs or ethanol. Avoid abrupt discontinuation. Some patients may develop tolerance.